Chugai Pharmaceutical Co., Ltd.
CHGCYOTCHealthcare● Active
$23.50
+$0.44(+1.91%)
Market Cap$77.4B
P/E Ratio—
52W High$34.84
52W Low$19.5
Chugai Pharmaceutical Co., Ltd. (CHGCY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CHGCY · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 24, 2026EPS Actual
$0.22
Revenue
$2.05B
Est. $2.15B · -4.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 24, 2026
After Market Close
▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
CHGCY reports quarterly as a OTC-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 23, 2026 | — | — | — | — | $2.16B | — |
| — Q2 FY2026 | Apr 24, 2026 | — | $0.22 | — | $2.05B | $2.15B | -4.7% |
| — Q1 FY2026 | Jan 29, 2026 | — | $0.25 | — | $2.56B | $1.84B | +39.4% |
| — Q4 FY2025 | Oct 24, 2025 | — | $0.23 | — | $2.26B | $2.06B | +9.6% |
| — Q3 FY2025 | Jul 24, 2025 | — | $0.20 | — | $2.00B | $2.20B | -9.0% |
| — Q2 FY2025 | Apr 24, 2025 | — | $0.19 | — | $1.98B | $1.82B | +8.8% |
| — Q1 FY2025 | Jan 30, 2025 | — | $0.18 | — | $1.92B | $1.87B | +2.5% |
| — Q4 FY2024 | Oct 25, 2024 | — | $0.22 | — | $2.12B | — | — |
Q3 FY2026
Jul 23, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 24, 2026
EPS Actual
$0.22
EPS Est.
—
EPS Surpr.
—
Revenue
$2.05B
Q1 FY2026
Jan 29, 2026
EPS Actual
$0.25
EPS Est.
—
EPS Surpr.
—
Revenue
$2.56B
Q4 FY2025
Oct 24, 2025
EPS Actual
$0.23
EPS Est.
—
EPS Surpr.
—
Revenue
$2.26B
Q3 FY2025
Jul 24, 2025
EPS Actual
$0.20
EPS Est.
—
EPS Surpr.
—
Revenue
$2.00B
Q2 FY2025
Apr 24, 2025
EPS Actual
$0.19
EPS Est.
—
EPS Surpr.
—
Revenue
$1.98B
Q1 FY2025
Jan 30, 2025
EPS Actual
$0.18
EPS Est.
—
EPS Surpr.
—
Revenue
$1.92B
Q4 FY2024
Oct 25, 2024
EPS Actual
$0.22
EPS Est.
—
EPS Surpr.
—
Revenue
$2.12B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2026 | $326B | $336B | $347B | 3 |
| Q2 FY2026 | $369B | $381B | $394B | 3 |
| Q1 FY2026 | $283B | $311B | $343B | 9 |
| Q4 FY2025 | $291B | $322B | $361B | 6 |
| Q3 FY2025 | $303B | $334B | $366B | 7 |
| Q2 FY2025 | $288B | $320B | $352B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | Apr 24, 2026 | — | $27.88 | $27.22 | -2.37% |
| — Q1 FY2026 | Jan 29, 2026 | — | $27.52 | $28.57 | +3.82% |
| — Q4 FY2025 | Oct 24, 2025 | — | $23.56 | $23.48 | -0.34% |
| — Q3 FY2025 | Jul 24, 2025 | — | $24.38 | $24.15 | -0.94% |
| — Q2 FY2025 | Apr 24, 2025 | — | $28.94 | $29.44 | +1.73% |
| — Q1 FY2025 | Jan 30, 2025 | — | $20.33 | $22.36 | +9.99% |
| — Q4 FY2024 | Oct 25, 2024 | — | $22.83 | $23.60 | +3.37% |
| — Q3 FY2024 | Jul 25, 2024 | — | $19.57 | $20.35 | +3.99% |
Q2 FY2026-2.37%
Report Date
Apr 24, 2026
EPS Beat/Miss
—
Price Before
$27.88
Price After
$27.22
Q1 FY2026+3.82%
Report Date
Jan 29, 2026
EPS Beat/Miss
—
Price Before
$27.52
Price After
$28.57
Q4 FY2025-0.34%
Report Date
Oct 24, 2025
EPS Beat/Miss
—
Price Before
$23.56
Price After
$23.48
Q3 FY2025-0.94%
Report Date
Jul 24, 2025
EPS Beat/Miss
—
Price Before
$24.38
Price After
$24.15
Q2 FY2025+1.73%
Report Date
Apr 24, 2025
EPS Beat/Miss
—
Price Before
$28.94
Price After
$29.44
Q1 FY2025+9.99%
Report Date
Jan 30, 2025
EPS Beat/Miss
—
Price Before
$20.33
Price After
$22.36
Q4 FY2024+3.37%
Report Date
Oct 25, 2024
EPS Beat/Miss
—
Price Before
$22.83
Price After
$23.60
Q3 FY2024+3.99%
Report Date
Jul 25, 2024
EPS Beat/Miss
—
Price Before
$19.57
Price After
$20.35
Beat Rate0 / 8 quarters
Largest Move+9.99% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CHGCY ends December
Chugai Pharmaceutical Co., Ltd. (CHGCY) most recently reported earnings on April 24, 2026 for Q2 FY2026, posting EPS of $0.22 (in line with the analyst consensus of —). The next CHGCY earnings date is expected around September 1, 2026.
Each quarter, investors track CHGCY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CHGCY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CHGCY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CHGCY earnings · 4 questionsChugai Pharmaceutical Co., Ltd.'s next earnings report is expected around September 1, 2026. CHGCY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CHGCY historically reports after market close (AMC).
CHGCY earnings datewhen is CHGCY earningsCHGCY next earnings datewhen does CHGCY report earningsCHGCY earnings calendar
▸ Source: FMP · Chugai Pharmaceutical Co., Ltd. SEC filings · US GAAP · Chugai Pharmaceutical Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026